‘I’m not at rock bottom yet’: I have a serious gambling addiction. I’ve maxed out my credit cards and racked up $100K in debt. Can you help?

I’ve gotten to a point where I need serious help for my gambling addiction, though I’m not at rock bottom yet. I am a journeyman-level employee with about 20 years’ experience at my current job. I am ...

The ‘best job in America’ pays over $120,000 a year — and offers a low-stress, healthy work-life balance

We’ve had the great resignation, quiet quitting, resistance to going back to the office — and now? It turns out people are looking for happiness, stability, flexibility and a good salary. In 2023, in ...

An Alzheimer’s Drug’s Big Surprise: What It Means

Until this past week, there seemed to be no answers to the Alzheimer’s puzzle. The leading theory of the disease, that it was caused by a buildup of beta amyloid plaque in the brain, had been disprove...

Autism Can Be a Growth Market, if Investors Help It Scale

Text size The Disability Opportunity Fund, Autism Impact Fund, the Difference Fund, and Divergent Ventures are just a few funds committed to investing in the autism and intellectual- or developmental-...

Axsome Stock Is Flying as Fast-Acting Depression Drug Wins FDA Approval

Text size The decision on the drug came a bit less than a year after the FDA’s self-imposed deadline on making a call had passed. Dreamstime The Food and Drug Administration issued a long-awaite...

Serena Williams pushes Selena Gomez’s startup to $100 million valuation

In the same Vogue feature where Serena Williams announced her possible retirement after the U.S. Open, the tennis star said she’ll continue to prioritize investment in women-owned businesses.  Days la...

Axsome Therapeutics Stock Soars on Proposed FDA Labeling for Depression Drug

Text size Axsome is reviewing the proposed labeling from the FDA. Dreamstime Shares of Axsome Therapeutics were soaring Monday after the biopharmaceutical company announced some good news in an attemp...

As Demand for Mental-Health Care Booms, Investors See Opportunities

Psychiatrists and psychologists once ran their own practices. Now the local therapist office could be controlled by a buyout king. Venture capitalists and private-equity firms are pouring billions of ...

Biogen Stock Has Fallen 50%. Why It’s Time to Buy.

Text size Biogen’s Alzheimer’s disease treatment was once expected to be a megablockbuster. Dominick Reuter/AFP via Getty Images Shares of the biotech firm Biogen are down 50% since June 1...

Biogen’s stock tumbles after the U.S. proposes restricting access to its Alzheimer’s disease drug

Biogen Inc.’s BIIB, -8.92% stock sank 9.3% in premarket trading on Wednesday, the day after regulators proposed limiting access to the class of Alzheimer’s disease drugs that includes the company’s th...

Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success

Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...